indolin-3-ol | 90005-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: indolin-3-ol
• 英文别名: 3-Hydroxy-indolin；2,3-dihydro-indol-3-ol；3-Hydroxyindoline；2,3-dihydro-1H-indol-3-ol
• CAS: 90005-39-3
• 化学式: C₈H₉NO
• mdl: MFCD19217111
• 分子量: 135.166
• InChiKey: PXHUCPJKTHEEPU-UHFFFAOYSA-N

物化性质

• 熔点：
  96 °C
• 沸点：
  276.1±29.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿；二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  indolin-3-ol 生成 吲哚
  参考文献：
  名称：

  isatin系列中的LiAlH 4还原。第一次沟通。关于3-羟基二氢吲哚的表征和性质†

  摘要：

  描述了通过LiAlH 4还原靛红，其导致3-羟基吲哚啉，吲哚，靛蓝和靛玉红的形成。

  DOI：

  10.1002/hlca.19570400602
• 作为产物：
  描述：

  N-乙酰基-3-吲哚啉酮 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 indolin-3-ol
  参考文献：
  名称：

  Synthesis and physical properties of various organic dyes derived from a single core skeleton, 1,2-dihydroindol-3-one

  摘要：

  Various organic dyes were synthesized from 1,2-dihydroindol-3-one analogue via Robinson ring annulation, which proceeded efficiently using DBU as a base to give the pi-expanded compounds. These compounds exhibited longer Stokes shifts (over 100 nm) than the 1,2-dihydroindol-3-ones (50-80 nm). Emission peaks of the obtained materials covered the 440-640 nm range. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.10.098

文献信息

• [EN] SYNTHESIS OF OLIGOMERIC NEOLIGNANS AND THEIR USE<br/>[FR] SYNTHÈSE DE NÉOLIGNANES OLIGOMÈRES ET LEURS APPLICATIONS
  申请人：UNIV COLUMBIA

  公开号：WO2010074764A1

  公开（公告）日：2010-07-01

  Compounds having the structure formule (I) and their uses are described herein.

  具有结构式(I)的化合物及其用途在此描述。
• [EN] SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS<br/>[FR] AGONISTES ET ANTAGONISTES SELECTIFS DU RECEPTEUR DE LA SOMATOSTATINE 1 ET/OU 4
  申请人：JUVANTIA PHARMA LTD OY

  公开号：WO2005033069A1

  公开（公告）日：2005-04-14

  The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.

  这项发明涉及基于(杂)芳基磺酰胺的肽类模拟物，其化学式为(I)，其中R1、R2、R3、A、B、D、Q、k和n的定义如所披露的，或其药学上可接受的盐或酯。化合物的化学式(I)具有对生长抑素受体亚型SSTR1和/或SSTR4的高亲和力和选择性，并可用于治疗或诊断需要与SSTR1和/或SSTR4相互作用的疾病或病况。
• [EN] SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS<br/>[FR] RECEPTEUR 1 ET/OU 4 DE SOMATOSTATINE, AGONISTES ET ANTAGONISTES SELECTIFS
  申请人：JUVANTIA PHARMA LTD OY

  公开号：WO2005033068A1

  公开（公告）日：2005-04-14

  The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R3, A, B, D, Q, h and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.

  这项发明涉及基于(杂)芳基磺酰胺的公式(I)的肽类模拟物，其中R1、R3、A、B、D、Q、h和j的定义如所披露的，或其药学上可接受的盐或酯。公式(I)的化合物具有对生长抑素受体亚型SSTR1和/或SSTR4的高亲和力和选择性，并可用于治疗或诊断需要与SSTR1和/或SSTR4相互作用的疾病或病况。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110263573A1

  公开（公告）日：2011-10-27

  The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及公式I的杂环联苯基环己基四氮杂苯并[ e ]吲哚，其中R1、R2和R3如本文所述。根据本发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制造、含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在治疗作用上对外周和中枢的功能障碍，如痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素的不适当分泌、肝硬化、肾病综合征、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等方面具有用途。